Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023. IBO cited Bruker’s double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength.

The IBO recognition follows Bruker’s three consecutive years of double-digit organic revenue growth. The fast growth can be attributed to the Bruker innovation model, management process and culture of disciplined entrepreneurialism, which have transformed the company’s product portfolio and addressable markets for sustainable above-market growth.

Commenting on the recognition of Bruker as the 2023 winner, Tanya Samazan, editor-in-chief of IBO, said: “We make our annual selection based on the criteria of financial and operational results, new product innovations and notable business developments. This year, Bruker was our standout choice.”

Frank H Laukien, President and CEO of Bruker, commented: “We are very pleased to have been recognized by this respected industry news report in a year when, according to IBO, ‘market conditions proved difficult for the lab tools industry in general.’ Our dual strategy of Project Accelerate 2.0 and Operational Excellence has built our company into an emerging leader in the post-genomic era. As previously stated, for 2024 we again expect excellent growth, with anticipated 8%-10% constant exchange rate (CER) revenue growth, well above-market organic revenue and non-GAAP EPS growth, as foundations for further expansion.”

Tanya Samazan added: “Bruker was the clear choice for our 2023 Company of the Year, not only because of its solid financial performance but also through its range of end markets and diverse product types that allow the company to capitalize on global trends such as clean energy, 3D chips and single cell proteomics. Congratulations to a well-deserving winner.”

IBO is an industry newsletter for the laboratory tools market that delivers the latest business developments, financial data, executive interviews and insight into market trends and opportunities. IBO is a publication of SDi, a division of Science and Medicine Group, which offers custom market research and strategic advisory services.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.